Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Invigor Medical vs Welling Health

Two GLP-1 desks, one scoreboard. We put Invigor Medical and Welling Health head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 9 · Grade B+

Invigor Medical

Visit Invigor Medical Full brief →
vs
No. 57 · Grade C

Welling Health

Visit Welling Health Full brief →

The verdict

Invigor Medical takes this head-to-head.

Invigor Medical scores 88 to 78 on our six-factor Brief Score — An established telehealth pharmacy with a broad metabolic and hormone catalog and a steady price line.

That doesn't make Welling Health a bad call — it's best for shoppers who want transparent flat-rate compounded glp-1s from a legitscript-certified, app-driven clinic. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
87
48
Supply Reliability
88
79
Transparency
84
88
Access Breadth
82
90
Clinical Oversight
88
89
Track Record
90
87
Invigor MedicalBrief Score 88 · 78Welling Health

Price, coverage & the tracker

Invigor MedicalWelling Health
Brief Score88/100 (B+)78/100 (C)
Semaglutide$199/moFrom $190/mo (compounded)
Tirzepatide$339/moFrom $275/mo (compounded)
CoverageNot disclosedAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
On the trackerStableprice stableNewnew to the tracker, no prior reading

Invigor Medical: Long-running operator; mid-market pricing unchanged this cycle.

Welling Health: New to the tracker on 1 August 2026. The published line reads From $190/mo (compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.